ZTS Quote, Financials, Valuation and Earnings

Elanco Animal Health, Inc. has a net margin of 30.04% compared to Zoetis, Inc.'s net margin of -2.99%. Zoetis, Inc.'s return on equity of 52.95% beat Elanco Animal Health, Inc.'s return on equity of 0.55%.

Zoetis, Inc. has a consensus price target of $158.22, signalling upside risk potential of 26.08%. On the other hand Elanco Animal Health, Inc. has an analysts' consensus of $25.00 which suggests that it could grow by 11.71%. Given that Zoetis, Inc. has higher upside potential than Elanco Animal Health, Inc., analysts believe Zoetis, Inc. is more attractive than Elanco Animal Health, Inc..

Zoetis, Inc. has a beta of 0.972, which suggesting that the stock is 2.841% less volatile than S&P 500. In comparison Elanco Animal Health, Inc. has a beta of 1.859, suggesting its more volatile than the S&P 500 by 85.894%.

Zoetis, Inc. has a quarterly dividend of $0.50 per share corresponding to a yield of 1.59%. Elanco Animal Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zoetis, Inc. pays 32.86% of its earnings as a dividend. Elanco Animal Health, Inc. pays out -- of its earnings as a dividend. Zoetis, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zoetis, Inc. quarterly revenues are $2.4B, which are larger than Elanco Animal Health, Inc. quarterly revenues of $1.1B. Zoetis, Inc.'s net income of $721M is higher than Elanco Animal Health, Inc.'s net income of -$34M. Notably, Zoetis, Inc.'s price-to-earnings ratio is 21.14x while Elanco Animal Health, Inc.'s PE ratio is 307.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis, Inc. is 5.97x versus 2.43x for Elanco Animal Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

IDEXX Laboratories, Inc. has a net margin of 30.04% compared to Zoetis, Inc.'s net margin of 24.85%. Zoetis, Inc.'s return on equity of 52.95% beat IDEXX Laboratories, Inc.'s return on equity of 66.88%.

Zoetis, Inc. has a consensus price target of $158.22, signalling upside risk potential of 26.08%. On the other hand IDEXX Laboratories, Inc. has an analysts' consensus of $766.00 which suggests that it could grow by 11.31%. Given that Zoetis, Inc. has higher upside potential than IDEXX Laboratories, Inc., analysts believe Zoetis, Inc. is more attractive than IDEXX Laboratories, Inc..

Zoetis, Inc. has a beta of 0.972, which suggesting that the stock is 2.841% less volatile than S&P 500. In comparison IDEXX Laboratories, Inc. has a beta of 1.668, suggesting its more volatile than the S&P 500 by 66.77%.

Zoetis, Inc. has a quarterly dividend of $0.50 per share corresponding to a yield of 1.59%. IDEXX Laboratories, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zoetis, Inc. pays 32.86% of its earnings as a dividend. IDEXX Laboratories, Inc. pays out -- of its earnings as a dividend. Zoetis, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zoetis, Inc. quarterly revenues are $2.4B, which are larger than IDEXX Laboratories, Inc. quarterly revenues of $1.1B. Zoetis, Inc.'s net income of $721M is higher than IDEXX Laboratories, Inc.'s net income of $274.6M. Notably, Zoetis, Inc.'s price-to-earnings ratio is 21.14x while IDEXX Laboratories, Inc.'s PE ratio is 54.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis, Inc. is 5.97x versus 13.46x for IDEXX Laboratories, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Moderna, Inc. has a net margin of 30.04% compared to Zoetis, Inc.'s net margin of -19.69%. Zoetis, Inc.'s return on equity of 52.95% beat Moderna, Inc.'s return on equity of -30.18%.

Zoetis, Inc. has a consensus price target of $158.22, signalling upside risk potential of 26.08%. On the other hand Moderna, Inc. has an analysts' consensus of $36.75 which suggests that it could grow by 12.21%. Given that Zoetis, Inc. has higher upside potential than Moderna, Inc., analysts believe Zoetis, Inc. is more attractive than Moderna, Inc..

Zoetis, Inc. has a beta of 0.972, which suggesting that the stock is 2.841% less volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.109, suggesting its more volatile than the S&P 500 by 10.882%.

Zoetis, Inc. has a quarterly dividend of $0.50 per share corresponding to a yield of 1.59%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zoetis, Inc. pays 32.86% of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend. Zoetis, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zoetis, Inc. quarterly revenues are $2.4B, which are larger than Moderna, Inc. quarterly revenues of $1B. Zoetis, Inc.'s net income of $721M is higher than Moderna, Inc.'s net income of -$200M. Notably, Zoetis, Inc.'s price-to-earnings ratio is 21.14x while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis, Inc. is 5.97x versus 5.68x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of 30.04% compared to Zoetis, Inc.'s net margin of 21.32%. Zoetis, Inc.'s return on equity of 52.95% beat Pfizer Inc.'s return on equity of 10.84%.

Zoetis, Inc. has a consensus price target of $158.22, signalling upside risk potential of 26.08%. On the other hand Pfizer Inc. has an analysts' consensus of $28.62 which suggests that it could grow by 14.36%. Given that Zoetis, Inc. has higher upside potential than Pfizer Inc., analysts believe Zoetis, Inc. is more attractive than Pfizer Inc..

Zoetis, Inc. has a beta of 0.972, which suggesting that the stock is 2.841% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

Zoetis, Inc. has a quarterly dividend of $0.50 per share corresponding to a yield of 1.59%. Pfizer Inc. offers a yield of 6.87% to investors and pays a quarterly dividend of $0.43 per share. Zoetis, Inc. pays 32.86% of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend. Zoetis, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Pfizer Inc.'s is not.

Zoetis, Inc. quarterly revenues are $2.4B, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Zoetis, Inc.'s net income of $721M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Zoetis, Inc.'s price-to-earnings ratio is 21.14x while Pfizer Inc.'s PE ratio is 14.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis, Inc. is 5.97x versus 2.28x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.